Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors-Reference-Cited by-同舟云学术

Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors

Published:2012-12 Issue:12 Volume:88 Page:937-941
ISSN:0378-3782
Container-title:Early Human Development
language:en
Short-container-title:Early Human Development

Author:

Mintz-Hittner Helen A.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Pediatrics, Perinatology, and Child Health

Reference15 articles.

1. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control;Gilbert;Early Hum Dev,2008

2. The international classification of retinopathy of prematurity revisited;The Committee for the Classification of Retinopathy of Prematurity;Arch Ophthalmol,2005

3. Standard image of plus disease in retinopathy of prematurity;Capone;Arch Ophthalmol,2006

4. Screening examination of premature infants for retinopathy of prematurity (policy statement);Section of Ophthalmology AAoP;Pediatrics,2006

5. Errata: screening examination of premature infants for retinopathy of prematurity (policy statement);Section of Ophthalmology AAoP;Pediatrics,2006

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity;International Ophthalmology;2024-07-02

2. Blindness is decreasing among children born preterm during the last four decades in Denmark;Acta Ophthalmologica;2024-01-08

3. Fluorescein Angiography Evaluation of Children Previously Treated with Anti-VEGF Monotherapy for Retinopathy of Prematurity;Retina;2023-12-26

4. Recurrence risk factors of intravitreal ranibizumab monotherapy in retinopathy of prematurity: a retrospective study at one center;International Journal of Ophthalmology;2023-01-18

5. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study;BMC Ophthalmology;2022-06-21